Lipocine Profit Margin

Lipocine (LPCN) currently reports a profit margin of -249.16% as of September 2026. That compares with -126.66% in the prior-year period — down 96.7% year over year. That is below the Healthcare sector average of 9.48%. Use the charts on this page to explore Lipocine's profit margin history and peer comparisons.

Lipocine's profit margin decreased from -126.66% to -249.16% — a 96.7% year-over-year decrease (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Lipocine's profit margin of -249.16% is lower than the Healthcare sector average of 9.48%. That is roughly 2728.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Lipocine's current -249.16% should be judged against Healthcare norms (sector average: 9.48%) and against LPCN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -249.16%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 9.48%. From there, open related valuation or income-statement pages for Lipocine, and consider following LPCN for alerts when major investors trade the stock.